PTH and chronic kidney disease: With current guidelines no longer recommending the routine use of calcitriol and active vitamin D due to increased risk of hypercalcaemia, and now a growing body of evidence suggesting that the current targets for vitamin D repletion may not be generalisable to CKD (levels of 25(OH)D ≥ 50 ng/mL may be required to control PTH) [60, 77], the optimal treatment strategies for patients with SHPT in non-dialysis CKD remain to be clearly defined.